4 studies found for: Bevirimat (PA-457) OR Bevirimat (PA-457)[TREATMENT] AND HIV [CONDITION] | Exclude Unknown
† Indicates status has not been verified in more than two years
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.
A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*